Pushkal Garg - 27 Feb 2026 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
EVP Chief R&D
Signature
By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg
Issuer symbol
ALNY
Transactions as of
27 Feb 2026
Net transactions value
-$1,533,100
Form type
4
Filing time
02 Mar 2026, 16:08:43 UTC
Previous filing
17 Feb 2026
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garg Pushkal EVP Chief R&D 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg 02 Mar 2026 0001829252

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $0 +1,908 +7.7% $0.000000 26,756 27 Feb 2026 Direct
transaction ALNY Common Stock Sale $41,773 -127 -0.47% $328.92 26,629 27 Feb 2026 Direct F1, F2
transaction ALNY Common Stock Sale $747,119 -2,259 -8.5% $330.73 24,370 27 Feb 2026 Direct F1, F3
transaction ALNY Common Stock Sale $384,197 -1,159 -4.8% $331.49 23,211 27 Feb 2026 Direct F1, F4
transaction ALNY Common Stock Sale $313,196 -942 -4.1% $332.48 22,269 27 Feb 2026 Direct F1, F5
transaction ALNY Common Stock Sale $46,815 -140 -0.63% $334.39 22,129 27 Feb 2026 Direct F1
holding ALNY Common Stock 431 27 Feb 2026 by Managed Account F6
holding ALNY Common Stock 250 27 Feb 2026 by Trust F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Restricted Stock Units Options Exercise $0 -1,908 -100% $0.000000 0 27 Feb 2026 Common Stock 1,908 Direct F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.90 to $329.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.08 to $331.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.09 to $332.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.11 to $333.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F7 Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F8 These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.
F9 On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.
F10 The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.